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Summary We could determine the S-phase fraction (SPF) by flow cytometric DNA analysis of paraffin archival material in 160 of 260 patients
with soft-tissue sarcoma of extremity and trunk wall. The prognostic value of SPF was compared with other clinicopathological factors. The
median follow-up time was 16 (6-31) years. In a univariate analysis, deep tumour location, increasing tumour size and histological
malignancy grade, microscopic tumour necrosis, vascular invasion, DNA non-diploidy and high SPF (>3.0%) were associated with poor
metastasis-free survival. In a multivariate analysis, microscopic tumour necrosis and high SPF were independently prognostic for metastasis.
Used in combination with tumour size, microscopic tumour necrosis and vascular invasion, SPF could identify a group of patients with a 5-
year metastasis-free survival rate of 0.97. This group constituted one-quarter of all patients. Patients with low SPF who did recur had a
prolonged clinical course both as regards metastases and local recurrence. We conclude that SPF is a valuable adjunct in prognostication in
soft-tissue sarcoma.
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The prognostic value ofcell proliferative activity has been investi-
gated in soft-tissue sarcoma using several methods. Proliferating
cell nuclear antigen (PCNA) and Ki-67 have been associated with
poor prognosis (Ueda et al, 1989; Stenfert Kroese et al, 1990; Oda
et al, 1993; Choong et al, 1994; Dreinhofer et al, 1994; Drobnjak
et al, 1994), whereas others have failed to show this (Herzberg et
al, 1992). Moreover, a high fraction of cells in S- or S+G2-phase,
as determined by flow cytometry, has been shown to be prognostic
(Becker et al, 1991; Alho et al, 1993) and has also been used to
identify patients with short-term response to chemotherapy
(Schmidt et al, 1993). In the present work, we have assessed DNA
ploidy status in 260 patients with soft-tissue sarcoma ofextremity
and trunk wall. In 160 ofthese tumours, the S-phase fraction (SPF)
could be calculated, and its prognostic value was analysed in rela-
tion to other clinicopathological factors.
MATERIALS AND METHODS
Patients
The population-based database at the Musculoskeletal Tumor
Center in Lund, Sweden, holds records of 508 patients with soft-
tissue sarcoma of extremity and trunk wall diagnosed between
1964 and 1989. Patients have been identified via the the Regional
Tumor Registry. The database therefore comprises all patients in
the Southern Swedish Health Care Region (1.5 million inhabi-
tants), irrespective ofwhether the patients have been treated at our
institution or at local hospitals in the region. Criteria for inclusion,
as well as classification of treatment, histopathology, including
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microscopic tumour necrosis, vascular invasion and malignancy
grading, have been described elsewhere (Gustafson 1994a).
In 260 ofthese 508 patients, flow cytometric DNA analysis has
been performed hitherto on paraffin-embedded material. SPF
could be calculated in 160 ofthese 260 patients. The 160 patients
had a median age of62 (range 18-87) years, and a median tumour
size of7 (range 1-30) cm. One patient had lymph node metastasis
at diagnosis. Malignant fibrous histiocytoma (MFH) was the
commonest histotype, and grade IV (four-grade scale) the
commonest malignancy grade (Table 1). All patients were oper-
ated on: 55 patients had inadequate local treatment (surgery with
an intralesional margin with or without radiotherapy or surgery
with a marginal margin without radiotherapy; 21 at the centre and
34 at non-centre hospitals), and 105 patients had adequate local
treatment (surgery with a marginal margin with radiotherapy or
surgery with a wide or radical margin with or without radio-
therapy; 93 at the centre and 12 at non-centre hospitals). Fourteen
patients receivedchemotherapy, two ofthese preoperatively. These
patients were not analysed separately, since they did not differ
from those who did not receive chemotherapy as regards clinico-
pathological factors or outcome.
Forty-six patients developed local recurrence, 27 of the 46
treated outside the centre and 19 ofthe 114 treated at the centre. At
latest follow-up, 58 patients had developed (distant) metastasis,
giving a 5-year metastasis-free survival rate (MFSR) of 0.66. The
median follow-up time for the 70 patients alive at last follow-up
was 16 (range 6-31) years.
Compared with the population-based database, the 160 patients
were a representative subset as regards age, sex, tumour localiza-
tion, tumour depth, tumour size, microscopic tumour necrosis,
vascular invasion, local treatment, metastasis rate and length of
follow-up. In the present series, tumours of malignancy grades I
and II were more common (28% vs 20% in the database), as were
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Table 1 Clinicopathological data, metastasis-free survival and uni-T and multivariate prognostic factors for metastasis in 160 surgically
treated patients with soft-tissue sarcoma of extremity and trunk wall
Factor Criteria n 5-year P-value Crude Multivariate
MFSR univariate metastasis analysis
analysis n RR(95%CI)
Age <62 years 80 0.66 0.8 32
>62 years 80 0.65 26
Sex Male 91 0.63 0.6 33
Female 69 0.69 25
Localization Upper extremity proximal 23 0.74 0.1 7
Upper extremity distal 10 0.75 2
Trunk wall 26 0.54 11
Lower extremity proximal 74 0.57 33
Lower extremity distal 27 0.89 5
Depth Subcutaneous 43 0.76 0.05 10
Deep-seated 117 0.62 48
Tumour size (cm) 1-5 56 0.76 0.05 14
6-10 67 0.63 25
11-15 24 0.57 12
16+ 13 0.48 7
Histotype MFH 49 0.65 0.15 16
Leiomyosarcoma 23 0.66 8
Liposarcoma 28 0.77 9
Synovial sarcoma 12 0.83 3
Other 48 0.55 22
Malignancy grade 10 1.00 <0.0001 0
11 35 0.82 7
III 54 0.74 17
IV 61 0.41 34
Tumour necrosis No 87 0.82 <0.0001 17
Yes 71 0.44 41 2.5 (1.3-4.8)
Vascular invasion No 128 0.70 0.0006 38
Yes 29 0.45 19
DNA types 1-2 73 0.79 0.001 19
3-8 87 0.54 39
S-phase fraction .3.0% 47 0.94 <0.0001 7
>3.0% 113 0.53 51 2.7 (1.1-6.8)
Microscopic tumour necrosis determined in 158 patients. Vascular invasion determined in 157 patients. MFSR, metastasis-free survival
rate. RR, relative risk. Cl, confidence interval.
liposarcoma (I18% vs 11% in the database). In addition, MFH was
less common in the present series (31% vs 43% in the database).
Flow cytometric DNA analysis
One representative block was chosen for disintegration and
analysis. A4-gm section adjacent to the 100-im section for disin-
tegration was stained withhaematoxylin and eosin and served as a
control to ensure that preserved and non-necrotic sarcoma tissue
was analysed. The DNA analysis was performed principally
according to the method described by Schutte et al (1985),
including treatment with trypsin and staining with propidium
iodide. The DNA content in individual nuclei was analysed in an
Ortho 50 H cytofluorograph (Baldetorp et al, 1989).
Ploidy status
The DNA histograms were classified into eight types depending
on the number ofpeaks and the pattern of the diploidG/G, peak.
A cell population was considered to show a G0/Gl peak and a
corresponding G2peak. Samples with one cell population showing
a narrow [coefficient of variation (CV) <7.5%] and Gaussian
Gd/GI distribution peak were classified as diploid (type 1),
whereas those with one cell population showing a broad (CV
.7.5%) and Gaussian distribution peak were classified as type 2,
and those with a skewed distribution peak as type 3 or type 4.
Among samples with two or more cell populations, four different
groups were defined: tetraploid (type 5), bimodality in the 2C
region (near-diploidy) (type 7), multiploid (type 8), and remaining
non-diploid (type 6) (Gustafson, 1994a). The histograms were
grouped into types 1-2 vs types 3-8, which we have shown gives
the bestprognostic separation (Gustafson, 1994b).
S-phase fraction
S-phase fraction (SPF) was calculated with a planimetric method
(Baisch et al, 1975), assuming the S-phase compartment to consti-
tute a rectangular distribution between the modal values of the
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Table 2 Comparison of clinicopathological data between 160 patients with soft-tissue sarcoma of the locomotor system in whom S-
phase fraction (SPF) could be calculated and 100 patients in whom SPF could not be calculated
Factor Criteria SPF calculated SPF not calculated P-value
(n=160) (n=100)
Age Mean(years) 59 63 0.07
Sex Male 91 55 0.8
Female 69 45
Localization Upper extremity proximal 23 14 0.4
Upper extremity distal 10 7
Trunk wall 26 8
Lower extremity proximal 74 51
Lower extremity distal 27 20
Depth Subcutaneous 43 36 0.12
Deep-seated 117 64
Tumour size Mean(cm) 8 8 0.7
Histotype MFH 49 47 0.007
Leiomyosarcoma 23 25
Liposarcoma 28 11
Synovial sarcoma 12 5
Other 48 12
Malignancy grade 10 3 0.0001
11 35 3
III 54 29
IV 61 65
Tumour necrosis No 87 43 0.2
Yes 71 56
Vascular invasion No 128 64 0.008
Yes 29 35
Microscopic tumour necrosis determined in 257 patients. Vascular invasion determined in 256 patients.
GO/G, and G2 peaks, and was expressed as the percentage ofnuclei
in the S-phase of the total number of nuclei. In case ofbimodality
in the 2C region, i.e. near-diploidy with a DNA index (DI) for the
non-diploid stemline below approximately 1.3, a mean SPF value
for the diploid and non-diploid stemline was calculated. When the
DI exceeded 1.3 and ifthe corresponding G2 peaks were distinctly
separated, the SPF was calculated exclusively for the non-diploid
stemline. In case of two or more non-diploid peaks, the SPF was
calculated in the most prominent non-diploid stemline.
SPF was not calculated if the corresponding G2 peak in the
histogram could not be identified, or if the non-diploid stemline
was small (G01GI <15% ofthe total number of observations), or if
the CV exceeded 8%, or if the contribution of debris in the SPF
compartment of the histogram was too extensive. Nuclear aggre-
gates were gated out using thresholding capabilities of the DNA
analysis software in the Ortho 2140 data handling system.
SPF could be calculated in 55 ofthe 61 type 1 histograms, in 18
of20 type 2 histograms, in five of six type 3 histograms, in two of
two type 4 histograms, in four ofeight type 5 histograms, in 45 of
99 type 6 histograms, in 16 of 17 type 7 histograms and in 15 of47
type 8 histograms. This comprised the 160 patients eligible for
analysis. The 100 patients in whom SPF could not be calculated
more often had tumours that were MFH or leiomyosarcoma, more
often of malignancy grade IV, and more often had vascular inva-
sion, but there were no differences as regards age, sex, localization,
depth, tumour size or microscopic tumour necrosis (Table 2).
These 100 patients had a 5-year MFSR of0.58 (P = 0.1 in compar-
ison with 5-year MFSR of0.66 in the 160 patients).
Statistics
The data were analysed using the Mann-Whitney U-test and
the chi-square test with the Yates' continuity correction when indi-
cated. Analyses of (distant) metastasis-free survival rates (MFSR)
were univariately performed with Kaplan-Meier methods and the
generalized Wilcoxon test. A Cox multivariate analysis of prog-
nostic factors for metastasis was performed, and the Wald statistic
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Figure 1 Metastasis-free survival in 160 patients with soft-tissue sarcoma of
extremity and trunk wall using S-phase fraction (SPF). P<0.0001
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was used for assessment of significant factors. A P-value <0.05
was considered significant. The analyses were performed by Jonas
Ranstam, PhD, CStat, Erdeven Medical Statistics, Lund, Sweden.
RESULTS
S-phase fraction
The median SPF value for the 160 patients was 6.0% (range
0.1-25%). We had no reason to assume that a specific SPF value
would be optimal for prognostic dichotomization, and therefore
analysed different cut-off values. We found the best cut-off at
3.0%, which identified 47 patients with SPF <3.0% (= low SPF)
and 113 patients with SPF >3.0% (= high SPF). The 5-year
MFSRs were 0.94 and 0.53 respectively (P <0.0001) (Figure 1).
Forty-three ofthe47 patients withtumours with low SPF and 53
ofthe 113 patients with tumours with high SPF had histograms of
types 1, 2, 3, 4 or 7. Among these five types, SPF could be calcu-
lated in 96 of 106 patients.
Correlation between SPF and other prognostic factors
The 47 patients with low SPF were younger, more often had
tumours of low malignancy grade, which were more often DNA
diploid, and were without microscopic tumour necrosis or vascular
invasion. They also less often had a leiomyosarcoma (Table 3).
Apart from a better prognosis, patients with low SPF also had a
prolonged clinical course; four of the seven patients who devel-
oped metastases did so after more than 5 years, compared with 2 of
51 in the patients with high SPF (P <0.0001) (Figure 1). The
median time to local recurrence was 27 months in the low-SPF
group, compared with 6 months in the high-SPF group (P <0.002).
These differences could notbe explainedby different treatments or
follow-up times. No other factor examined (age, sex, localization,
tumour depth, tumour size, histotype, malignancy grade, micro-
scopic tumour necrosis, vascular invasion or DNA ploidy) could
identify patients with a prolonged clinical course as well as
low SPF did.
Uni and multivariate analysis of prognostic factors
By univariate analysis, deep tumour position, increasing tumour
size and malignancy grade, microscopic tumour necrosis, vascular
invasion, DNA types 3-8 and high SPF reduced metastasis-free
survival. In a Cox model of 157 patients, microscopic tumour
necrosis and high SPF were independent prognostic factors for
metastasis (Table 1). The other factors lost their prognostic influ-
ence as a result ofcovariations with the independent factors.
Table 3 Correlations between S-phase fraction (SPF) and other clinicopathological factors in 160 patients with soft-tissue sarcoma of
extremity and trunk wall
Factor Criteria Low SPF High SPF P-value
(<3.0 %) (> 3.0 %)
(n=47) (rn113)
Age Mean (years) 53 62 0.005
Sex Male 25 66 0.5
Female 22 47
Localization Upper extremity proximal 6 17 0.4
Upper extremity distal 3 7
Trunk wall 4 22
Lower extremity proximal 23 51
Lower extremity distal 11 16
Depth Subcutaneous 13 30 0.9
Deep-seated 34 83
Tumour size Mean(cm) 9 8 0.4
Histotype MFH 12 37 0.007
Leiomyosarcoma 1 22
Liposarcoma 14 14
Synovial sarcoma 5 7
Other 15 33
Malignancy grade 7 3 0.0001
11 22 13
III 14 40
IV 4 57
Tumour necrosis No 34 53 0.008
Yes 12 59
Vascular invasion No 44 84 0.01
Yes 2 27
DNA types 1-2 35 38 0.0001
3-8 12 75
Microscopic tumour necrosis determined in 158 patients. Vascular invasion determined in 157 patients.
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c-1 We applied SPF as an adjunct to our earlierproposedprognostica-
tion system, based on the three risk factors, tumour size >10 cm,
\ §, { B microscopic tumour necrosis and vascular invasion (Gustafson,
.................. 1994a). This could be done in 157 of the 160 patients. We found
that in the group of 116 patients with no or one risk factor, SPF
C could further sharpen the prognostication; in this subgroup, 38
patients with low SPF had a 5-year MFSR of 0.97 [95% confi-
D dence interval (CI) 0.92-1.0], compared with 0.65 (CI 0.53-0.76)
in 78 patients with high SPF (P = 0.0003) (Figure 2). Among the
41 patients with two or three risk factors, eight patients with
low SPF had a 5-year MFSR of 0.75, compared with 0.26 in 33
0 3 6 9 12 15 patients with high SPF, but this difference diminished over time
and was not statistically significant (P = 0.1) (Figure 2). Among Years the 38 patients with low SPF, 10 tumours were of malignancy
grade III (Table 4).
Figure 2 Metastasis-free survival in prognostic subsets of 157 patients with
soft-tissue sarcoma of extremity and trunk wall. Lowrisk, no or one factor of
tumour size >11 cm, microscopic tumour necrosis or vascular invasion.
Highrisk, two or three of above. SPF, S-phase fraction. A, Lowrisk/low SPF
(n-38). B, Highrisk/low SPF (n=8). C, LowriskJhigh SPF (nr78). D,
Highrisk/high SPF (n=33). P-value for lowrisk group = 0.0003. P-value for
highrisk group = 0.1
DISCUSSION
S-phase fraction (SPF) has been identified as a prognostic factor in
several malignancies, breast cancer, non-small-cell lung cancer,
colorectal cancer and carcinoma of the ovary (for review, see
Merkel and McGuire, 1990). In soft-tissue sarcoma, several
markers of proliferation have yielded prognostic information
Table 4 Comparison of clinicopathological factors in 116 patients with low-risk soft-tissue sarcoma of extremity and trunk wall
subdivided using S-phase fraction (SPF)
Factor Criteria Low SPF High SPF P-value
(<3.0 %) (>3.0 %)
(n=38) (n=78)
Age Mean (years) 55 63 0.02
Sex Male 21 47 0.6
Female 17 31
Localization Upper extremity proximal 6 14 0.4
Upper extremity distal 3 6
Trunk wall 2 14
Lower extremity proximal 19 32
Lower extremity distal 8 12
Depth Subcutaneous 13 24 0.7
Deep-seated 25 54
Tumour size Mean (range) cm 8 (1-26) 6 (1-17) 0.7
Histotype MFH 10 22 0.02
Leiomyosarcoma 1 17
Liposarcoma 13 10
Synovial sarcoma 3 6
Other 11 23
Malignancy grade 6 3 0.0001
11 22 12
III 10 33
IV 0 30
Tumour necrosis No 34 53 0.01
Yes 4 25
Vascular invasion No 38 73 0.03
Yes 0 5
DNA types 1-2 28 32 0.001
3-8 10 46
Low-risk defined as having no or one of the prognostic factors tumour size >11 cm, microscopic tumour necrosis or vascular invasion.
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(Ueda et al, 1989; Stenfert Kroese et al, 1990; Becker et al, 1991;
Alho et al, 1993; Oda et al, 1993; Choong et al, 1994; Dreinhofer
et al, 1994; Drobnjak et al, 1994), but SPF has not been thoroughly
tested together with other strong clinicopathological factors in a
multivariate analysis.
In 100 of 260 samples, SPF could not be calculated, a fact that
restricts the usefulness of the method. These 100 patients had a
different distribution of histotypes and malignancy grades and a
worse 5-year MFSR, implying that these 100 patients may belong
to a different subset of soft-tissue sarcoma patients. The reasons
for the failures in calculation were primarily: (1) the histogram
showed a high background distribution; (2) the non-diploid peak
represented less than 15% of the observations in the histogram;
and (3) the coefficient of variation (CV) was over 8%. If one of
these criteria is fulfilled, SPF should, according to international
consensus guidelines, not be calculated (Shankey et al, 1993). In
the 100 patients in whom calculation of SPF failed, these
phenomena were more often seen, and they may reflect a more
malignant tumour. The number offailures may be reduced iffresh
tumour tissue is examined, since paraffin-embedded tissue
normally, owing to preparation artefacts, gives a higher back-
ground contribution than does fresh tissue (Hedley, 1989). By
using fresh material instead ofparaffin material, we have in recent
years been able to reduce the failure rate to less than 30%, and we
are now investigating whether other algorithms for calculation of
SPF can reduce this rate further.
Our cut-off value of 3% for low- and high-SPF value was
arrived at after an a posteriori analysis. There is no consensus on
the cut-off value of SPF in soft-tissue sarcoma using paraffin
archival material. Our cut-off, proposed in this exploratory work,
has to be tested in other series.
In a univariate analysis, several factors were associated with
metastasis, among them microscopic tumour necrosis and high
SPF, which were the sole factors that retained their prognostic
value in a multivariate analysis. Two other series (Alho et al, 1993;
Huuhtanen et al, 1995) have shown a prognostic value of SPF in
soft-tissue sarcoma, but none of the series have used multivariate
analysis. When combined with our earlier proposed prognostica-
tion system using tumour size . 11 cm, microscopic tumour
necrosis and vascular invasion (Gustafson, 1994a), SPF could
identify a group as large as one-quarter (38 of 157) of all patients
with virtually benign soft-tissue sarcomas; the MFSR was 0.97
after more than 10 years of follow-up. This group contained no
patients with tumours ofmalignancy grade IV, but ten patients had
a grade III tumour, which shows the difficulties in correctly
predicting prognosis using conventional histological malignancy
grading. Furthermore, 43 of47 patients with low SPF had tumours
with histogram types 1, 2, 3, 4 and 7, and in these histogram types
SPF could be calculated nine times of ten. Patients with two or
three risk factors and also a high SPF had a poor prognosis, and
may be suitable candidates for trials with adjuvant therapy. In
patients with tumours with low SPF, four ofseven metastases were
detected after more than 5 years of follow-up. Also, the median
time to local recurrence was longer in this group. This should be
contrasted with our large population-based series, in which around
90% of metastases and local recurrences were detected within 3
years after diagnosis of the primary tumour (Gustafson, 1994a).
This finding is of clinical importance; low SPF may identify a
group of patients who may be at risk of developing metastasis
and/or local recurrence for a longer time period, and may require a
longer follow-up period.
We conclude that SPF as determined by FCM is, together with
microscopic tumour necrosis, an independent prognostic factor for
metastasis in soft-tissue sarcoma. The high overall failure rate
(40%) mustbe noted, but since this rate was only 10% in the group
in which the prognostic influence was strongest, it should not limit
the usefulness. It may, in combination with our earlier prognosti-
cation system, identify patients with a very good prognosis.
Furthermore, it may be used to identify patients who require a
longer follow-up.
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